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PACKGROUND& AIMS: Patients carrying germline mu-
ations of LKB1 have an increased risk of pancreatic cancer;
owever, it is unclear whether down-regulation of LKB1 is
n important event in sporadic pancreatic cancer. In this
tudy, we aimed to investigate the impact of LKB1 down-
egulation for pancreatic cancer in mouse and human and
o elucidate the mechanism by which Lkb1 deregulation
ontributes to this disease. METHODS: We first investi-
ated the consequences of Lkb1 deficiency in a genetically
odified mouse model of pancreatic cancer, both in terms
f disease progression and at the molecular level. To test the
elevance of our findings to human pancreatic cancer, we
nvestigated levels of LKB1 and its potential targets in hu-
an pancreatic cancer. RESULTS: We definitively show
hat Lkb1 haploinsufficiency can cooperate with oncogenic
rasG12D to cause pancreatic ductal adenocarcinoma (PDAC)
n the mouse. Mechanistically, this was associated with
ecreased p53/p21-dependent growth arrest. Haploinsuffi-
iency for p21 (Cdkn1a) also synergizes with KrasG12D to
rive PDAC in the mouse. We also found that levels of
KB1 expression were decreased in around 20% of human
DAC and significantly correlated with low levels of p21
nd a poor prognosis. Remarkably, all tumors that had low
evels of LKB1 had low levels of p21, and these tumors did
ot express mutant p53. CONCLUSIONS: We have iden-
ified a novel LKB1-p21 axis that suppresses PDAC follow-
ng Kras mutation in vivo. Down-regulation of LKB1 may
herefore serve as an alternative to p53 mutation to drive
ancreatic cancer in vivo.
eywords: Pancreatic Cancer; Kras; LKb1; p21.
ancreatic cancer is the fourth most common cause of
cancer deaths worldwide, with an estimated 5-year
verall survival of 5%.1 The highly aggressive nature of
his disease, combined with the anatomical location ofumors, results in 90% of patients having surgically un-
esectable disease at the time of diagnosis.2 The pancreas
onsists of 3 main cell types—islet cells, acinar cells, and
uct cells. Tumors can arise from any of these cell types,
ut approximately 90% of cases are pancreatic ductal
denocarcinoma (PDAC). PDAC arises from precursor
esions called pancreatic intraepithelial neoplasms
PanINs).3 The formation of PanIN lesions and the pro-
ression to invasive adenocarcinoma are driven by acti-
ation of the KRAS oncogene in about 90% of cases,4
ccompanied by loss of function of tumor suppressors,
ost commonly the Ink4a, p53, and Smad4 tumor sup-
ressors.3
Certain inherited genetic lesions have also been shown
o confer a predisposition to pancreatic cancer. Muta-
ions in the LKB/STK11 tumor suppressor gene result in
he Peutz–Jeghers syndrome,5,6 an autosomal-dominant
ondition characterized by hamartomatous polyps of the
astrointestinal tract and a dramatically increased risk of
pithelial malignancies at other sites, including a 100-
old increased risk of pancreatic cancer.7-9 Restoration of
ilenced LKB1 in human pancreatic carcinoma cells in-
uces apoptosis in vitro.10 Furthermore, LKB1 gene inac-
ivation has been observed in intraductal papillary muci-
ous neoplasms of the pancreas.11
Lkb1 knockout mice are not viable, and embryos sur-
ive only until embryonic day E9.5 because of neural tube
efects and vascular abnormalities.12 However, Lkb1/
ice are viable and mirror human Peutz–Jeghers syn-
rome in that they develop benign intestinal polyps
Abbreviations used in this paper: AMPK, adenosine monophosphate–
ctivated protein kinase; PanIN, pancreatic intraepithelial neoplasia;
DAC, pancreatic ductal adenocarcinoma.
© 2010 by the AGA Institute
0016-5085/$36.00doi:10.1053/j.gastro.2010.04.055
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August 2010 LKB1 DEFICIENCY AND PANCREATIC CANCER 587hamartomas) and have an increased risk of a range of
ancers later in life.13-16 However, the consequences of
kb1 deficiency in the pancreas have not been well-stud-
ed thus far, and the mechanisms by which its loss may
ontribute to pancreatic cancer are unknown.
Lkb1 encodes a serine/threonine kinase that activates
number of downstream kinases, including the adeno-
ine monophosphateactivated protein kinase (AMPK),
hich responds to energy stress by negatively regulating
he mammalian target of rapamycin kinase.17 Lkb1 is
lso able to regulate cell growth and apoptosis, poten-
ially through interaction with the tumor suppressor
53.18 Ectopic expression of Lkb1 in cells lacking the
ndogenous protein induces p21 expression and cell-
ycle arrest in a p53-dependent manner, and Chromatin
mmunoprecipitation analysis has revealed that Lkb1 is
ecruited to the p21 promoter by p53.19-21 Lkb1 deficiency
as also been shown to prevent culture-induced senes-
ence, although paradoxically it renders cells resistant to
ubsequent transformation by Ha-Ras.13
Using cre-lox technology to target endogenous ex-
ression of KrasG12D to the mouse pancreas through
he Pdx1 pancreatic progenitor cell gene promoter re-
ults in formation of PanINs.22 However, these lesions
ail to rapidly progress and only develop into invasive
ancreatic adenocarcinoma at low frequency unless
dditional genetic lesions are introduced. In this study,
e have assessed whether Lkb1 loss can promote tu-
origenesis in this model and found a dramatic accel-
ration of tumorigenesis in mice carrying a single
onditional knockout allele of Lkb1. We have also
emonstrated that this is associated with decreased
21-dependent growth arrest.
Materials and Methods
Genetically Modified Mice and Animal Care
The Pdx1-Cre, LSL-KrasG12D, Lkb1flox/flox, and Cdkn1a/
ice have been described previously.23-26 For further informa-
ion, see Supplementary Materials.
Immunohistochemistry
Immunohistochemical analysis was performed on
ormalin-fixed paraffin-embedded sections according to
tandard protocols. For detailed protocols, see Supple-
entary Materials.
Senescence-Associated -Galactosidase
Staining
We stained cryosections of mouse pancreas or tu-
or for senescence-associated -galactosidase activity ac-
ording to manufacturer’s protocol (Cell Signaling Tech-
ology, Danvers, MA) and counterstained them with
uclear fast red solution. KLaser Capture Microdissection and RNA
Isolation
Frozen tissue was sectioned (at 15–20 m) onto
ALM-PEN membrane slides and lightly stained with
ematoxylin. Laser capture microdissection was per-
ormed using the P.A.L.M. MicroLaser System. RNA was
solated with the RNA easy extraction kit (Qiagen,
ilden, Germany).
Reverse-Transcription Polymerase Chain
Reaction
Total RNA was reverse transcribed to complemen-
ary DNA using the Superscript III kit (Invitrogen, Carlsbad,
A) according to manufacturer’s instructions. For further
nformation and primers, see Supplementary Materials.
Immunoblotting
Tissue samples were homogenized into supple-
ented Tissue Protein Extraction Reagent (Thermo Sci-
ntific, Waltham, MA) in the Precellys 24 (Stretton Scientific,
tretton, UK). Lysates were resolved by 10% Bis-Tris gel elec-
rophoresis (Invitrogen). Proteins were transferred to polyvi-
ylidene difluoride membrane, blocked, and probed with an-
ibodies against Lkb1 (Cell Signaling Technology) 1:1000;
hospho-AMPK (Cell Signaling Technology) 1:1000, and
-tubulin (Sigma) 1:5000.
Tissue Microarray Analysis
The human pancreatico-biliary tissue microarray
as created within the West of Scotland Pancreatic Unit,
niversity Department of Surgery, Glasgow Royal Infirmary.
or further information, see Supplementary Materials.
Results
Lkb1 Heterozygosity Accelerates
KrasG12D-Induced Pancreatic Cancer
To determine whether Lkb1 deficiency could act
n synergy with activated Kras signaling to promote pan-
reatic tumorigenesis, we crossed Lkb1flox/ mice to Pdx1-
re, KrasG12D/ mice to generate cohorts of Pdx1-Cre,
rasG12D/ (KC), Pdx1-Cre, Lkb1flox/ (LC), and Pdx1-Cre,
rasG12D/, Lkb1flox/ (KLC) mice.25 These mice were mon-
tored for pancreatic tumor development and sacrificed
t intervals, or as they showed signs of disease. Postmor-
em analysis was performed and tumors were diagnosed
n the basis of gross pathology. The median time to
DAC of Pdx1-Cre, KrasG12D/, Lkb1flox/ (KLC) mice was
ust 141 days (n 20, Kaplan–Meier curve, Figure 1A). As
eported previously, Pdx1-Cre, KrasG12D/ (KC) mice devel-
ped PanIN lesions within the pancreas that rarely pro-
ressed to adenocarcinoma within the 18-month dura-
ion of our experiment (n  20).22 Pdx1-Cre, Lkb1flox/
LC) mice remained disease-free for the duration of the
xperiment (n  20). A small subset of the Pdx1-Cre,
rasG12D/, Lkb1flox/ (KLC) mice exhibited Cre-mediated
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588 MORTON ET AL GASTROENTEROLOGY Vol. 139, No. 2ecombination in their cecum, leading to intussuscep-
ions, with a median onset of 47 days. These are not
ncluded in the Kaplan–Meier curve (Figure 1A).
This increased pancreatic cancer predisposition was
ot limited to invasive tumors; the number of PanINs
bserved in 6-week-old Pdx1-Cre, KrasG12D/, Lkb1flox/
KLC) mice was significantly increased when compared
ith Pdx1-Cre, KrasG12D/ (KC) mice (Figure 1B, P  .007).
n addition, we also observed an increase in PanIN 2 and
anIN 3 lesions compared with KC mice (Figure 1C).
igure 1. Lkb1 heterozygosity combined with KrasG12D is sufficient to in
urvival of Pdx1-Cre Lkb1flox/ (LC, green dashed line), Pdx1-Cre Kra
ashed line) mice. (B) Boxplot showing number of pancreatic intraep
ild-type, KC, and KLC mice (n  6 mice per genotype) as indicate
istopathological section of pancreas from wild-type, KC, and KLC mice
uct, a PanIN lesion, and an Alcian bluestained section of a PanIN le
&E-stained sections of pancreatic ductal adenocarcinoma (PDAC) aris
xhibiting increased lymphocytic involvement.istological sections of tumors arising in Pdx1-Cre, mrasG12D/, Lkb1flox/ (KLC) animals were analyzed to as-
ertain the phenotype of these PanINs and tumors.
anIN lesions exhibited characteristic histologic changes
f the normal duct, including expansion of the cytoplasm
ith associated mucin accumulation, which was con-
rmed by Alcian blue staining (Figure 1D, right), forma-
ion of papillary architecture, loss of polarity, appearance
f atypical nuclei, and luminal budding (Figure 1D). A
ajority of Pdx1-Cre, KrasG12D/, Lkb1flox/ (KLC) tumors
ere PDAC (Figure 1E); however, some tumors exhibited a
pancreatic cancer. (A) Kaplan–Meier survival curve showing tumor-free
/ (KC, red solid line), and Pdx1-Cre KrasG12D/ Lkb1flox/ (KLC, blue
l neoplasia (PanINs) per histopathological section of pancreas from
 .007). (C) Boxplot showing number of PanINs of grades 13 per
6 mice per genotype) as indicated. (D) H&E-stained sections of a normal
arising in the pancreas of a 6-week-old KLC mouse, as indicated. (E)
KLC mice, with some tumors exhibiting a cystic component and othersduce
sG12D
ithelia
d (P
(n
sion
ing inore cystic morphology (Figure 1E, middle panel), and en-
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August 2010 LKB1 DEFICIENCY AND PANCREATIC CANCER 589anced immune cell infiltration was apparent in some tu-
ors (Figure 1E, right panel), compared with the small num-
er of tumors observed in older Pdx1-Cre, KrasG12D/ (KC)
ice. Our results show that Lkb1 deficiency can synergize
ith activated Kras to induce pancreatic tumor formation.
Homozygous Loss of Lkb1 Is Sufficient to
Initiate Pancreatic Tumorigenesis
We also investigated whether loss of Lkb1 as a sole
nitiating genetic event was sufficient to induce pancre-
tic tumor formation in the mouse. We crossed Lkb1flox/
ice to Pdx1-Cre mice and interbred the offspring to
enerate cohorts of Pdx1-Cre Lkb1flox/ (LC) and Pdx1-Cre
kb1flox/flox (LLC) mice. We found that Pdx1-Cre Lkb1flox/flox
LLC) mice develop pancreatic tumors with an incidence
f 100% and a median survival of 68 days, while Pdx1-Cre,
kb1flox/ (LC) mice remained disease-free for 500 days
Figure 2A). Pdx1-Cre Lkb1flox/flox (LLC) mice presented
ith abdominal distention, and tumors arising in these
ice were mucinous cystadenomas characterized by the
resence of multiple large cysts, in some cases at the expense
igure 2. Homozygous loss of Lkb1 is sufficient to initiate pancreatic tu
dx1-Cre Lkb1fl/ mice (LC, green dashed line), Pdx1-Cre Lkb1fl/fl mice
dx1-Cre KrasG12D/ Lkb1fl/mice (KLC, blue solid line). (B) Gross patho
ections of cystic pancreatic tumors arising in LLC mice. (E) Alcian bluef most of the normal pancreas tissue (Figure 2B–E). mumors also exhibited excessive mucin production, as
onfirmed by Alcian blue staining (Figure 2E). We con-
lude that Lkb1 loss as a sole event is sufficient to initiate
ancreatic tumor growth; however, those tumors are be-
ign mucinous cystadenomas and Lkb1 loss alone is not
ufficient to drive formation of PDAC. These results
gree with a previous analysis of mice lacking Lkb1 spe-
ifically within the pancreas, in which mice developed
ancreatic serous cystadenomas.27
Lkb1 Haploinsufficiency Synergizes With
KrasG12D to Induce Pancreatic Cancer
Because Pdx1-Cre, Lkb1flox/ (LC) mice did not de-
elop any disease, and Pdx1-Cre Lkb1flox/flox (LLC) mice
eveloped pancreatic tumors with a very short latency, we
ondered whether the tumor phenotype we observed in
dx1-Cre, KrasG12D/, Lkb1flox/ (KLC) mice was a result of
omplete loss of Lkb1 by loss of heterozygosity. Immu-
ohistochemical analysis was performed to ascertain lev-
ls of Lkb1 in lesions and tumors from Pdx1-Cre,
rasG12D/ (KC), and Pdx1-Cre, KrasG12D/, Lkb1flox/ (KLC)
genesis. (A) Kaplan–Meier survival curve showing tumor-free survival of
, blue dashed line), Pdx1-Cre KrasG12D/ mice (KC, red solid line), and
f a cystic pancreatic tumor arising in an LLC mouse. (C, D) H&E-stained
ined section of a cystic pancreatic tumor arising in an LLC mouse.mori
(LLC
logy oice. Lkb1 was detected in the nucleus and cytoplasm of
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590 MORTON ET AL GASTROENTEROLOGY Vol. 139, No. 2ormal duct cells and Pdx1-Cre, KrasG12D/ (KC) PanIN
esions and tumors as expected (Figure 3A),28 but also in
esions and tumors from Pdx1-Cre, KrasG12D/, Lkb1flox/
KLC) mice (Figure 3B), indicating maintenance of the
ild-type allele. As a control, Lkb1 immunohistochemistry
as also carried out on tumors from Pdx1-Cre Lkb1flox/flox
igure 3. Lkb1 haploinsufficiency synergizes with KrasG12D to induce p
uct, pancreatic intraepithelial neoplasia (PanIN), and pancreatic duc
ndicated. (B) Immunohistochemical analysis of Lkb1 levels in normal d
C) Immunohistochemical analysis of Lkb1 levels in cystadenoma arising
y reverse-transcription polymerase chain reaction in tissue microdissec
-actin serves as control for RNA quantity and integrity. (E) Quan
hosphoadenosine monophosphateactivated protein kinase (AMPK
LC mice. Levels were normalized against -tubulin levels.LLC) mice, and no Lkb1 was detected (Figure 3C). rLaser capture microdissection was also performed to
solate tissue from preneoplastic PanIN lesions and tu-
ors arising in Pdx1-Cre, KrasG12D/, Lkb1flox/ (KLC) mice,
nd reverse-transcriptase polymerase chain reaction anal-
sis showed transcription of wild-type Lkb1 in the result-
ng tumors (Figure 3D). Further, immunoblot analysis
atic cancer. (A) Immunohistochemical analysis of Lkb1 levels in normal
enocarcinoma (PDAC) arising in Pdx1-Cre KrasG12D/ (KC) mice, as
anIN, and PDAC arising in Pdx1-Cre KrasG12D/ Lkb1flox/ (KLC) mice.
Pdx1-Cre Lkb1flox/flox (LLC) mouse. (D) Detection of the Lkb1 transcript
rom lesions in frozen sections harvested from KC, KLC, and LLC mice.
tion of Western immunoblotting analysis of Lkb1 (top panel) and
tom panel) protein levels in pancreatic tumor lysates from KC, KLC, andancre
tal ad
uct, P
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; botevealed only a decrease in Lkb1 levels, and a reduction in
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August 2010 LKB1 DEFICIENCY AND PANCREATIC CANCER 591hosphorylation of the Lkb1 target, AMPK, in Pdx1-Cre,
rasG12D/, Lkb1flox/ (KLC) tumors, compared with the
lmost complete loss observed in tumors from Pdx1-Cre
kb1flox/flox (LLC) mice (Figure 3E, Supplementary Figure
). These results demonstrate that Lkb1 is a haploinsuf-
cient pancreatic tumor suppressor, and that lack of only
allele is sufficient, when combined with Kras mutation,
o cause PDAC.
Lkb1 Deficiency Limits Expression of the Tumor
Suppressors p53 and p21 in PanIN Lesions
We sought to further delineate the mechanism by
hich Lkb1 haploinsufficiency synergizes with activated
ras to promote pancreatic tumorigenesis. Consistent
ith its in vivo tumor suppressor function, Lkb1 defi-
iency has been shown to prevent culture-induced senes-
ence.13 Re-expression of Lkb1 in cancer cell lines deficient
or Lkb1 has also been shown to result in p53-dependent
ell-cycle arrest and enhanced expression of p21.19,20 On
he basis of these results, we wondered whether Lkb1
ight act to suppress pancreatic tumorigenesis by pro-
oting growth arrest in vivo through transcriptional
ctivation of p21, because preneoplastic pancreatic le-
ions in Elas-tTA/tetO-Cre, KrasG12V mice have previously
een reported to undergo oncogene-induced senescence,
s indicated by positive staining for a number of senes-
ence markers.29 We hypothesized that preneoplastic le-
ions in our Pdx1-Cre, KrasG12D/, Lkb1flox/ (KLC) mice
ould exhibit diminished p21 and p53 expression com-
ared with those lesions found in Pdx1-Cre, KrasG12D/
KC) mice. We performed immunohistochemical analysis
or both p21 and p53 in PanIN lesions in these mice.
igh levels of both p21 and p53 were observed in PanINs
rising in Pdx1-Cre, KrasG12D/ (KC) mice (Figure 4A, Sup-
lementary Figure 2), compared with normal ducts in
hese mice, as expected (data not shown). Significantly,
owever, in PanIN lesions arising in Pdx1-Cre, KrasG12D/,
kb1flox/ (KLC) mice, we observed a considerable re-
uction in levels of p21 and of p53 (Figure 4B, Sup-
lementary Figure 2). We quantified the proportion of
ells staining positive for p21 and p53 expression in
anINs from both Pdx1-Cre, KrasG12D/ (KC) and Pdx1-
re, KrasG12D/, Lkb1flox/ (KLC) mice and confirmed
hat expression of both was significantly reduced in
dx1-Cre, KrasG12D/, Lkb1flox/ (KLC) PanINs with a
edian of 14.3% p21-positive cells and 12.0% p53-
ositive cells, compared with 32.2% and 36.1%, respec-
ively, in Pdx1-Cre, KrasG12D/ (KC) PanINs (Figure 4C, P
.002; Figure 4D, P  .004). Quantitative real-time
olymerase chain reaction analysis performed on mi-
rodissected tissue demonstrated that transcription of
21 is also decreased in Pdx1-Cre, KrasG12D/ Lkb1flox/
KLC) mice, to 0.64% of the levels observed in Pdx1-Cre,
rasG12D/ (KC) PanINs (data not shown).
In light of these observations, we also wanted to examine
hether preneoplastic lesions in Pdx1-Cre, KrasG12D/ (KC) aice exhibited signs of growth arrest, implying that Lkb1
eficiency could alter this phenotype through diminished
21 expression. We therefore performed -galactosidase
taining, indicative of senescence (or long-term growth
rrest), to address this question. We observed -galacto-
idase staining in PanIN lesions and tumors from Pdx1-
re, KrasG12D/ (KC) mice (Figure 4A), thus confirming
revious reports. However, we were unable to detect pos-
tive staining in premalignant lesions or tumors in Pdx1-
re, KrasG12D/, Lkb1flox/ (KLC) mice (Figure 4B). Con-
ersely, staining for the proliferation marker Ki67
howed that PanIN lesions in 6-week-old Pdx1-Cre,
rasG12D/, Lkb1flox/ (KLC) mice were highly proliferative,
hile lesions in age-matched Pdx1-Cre, KrasG12D/ (KC)
ice exhibited lower levels of staining (Figure 4A and B).
e quantified levels of Ki67 in Pdx1-Cre, KrasG12D/ (KC)
nd Pdx1-Cre, KrasG12D/, Lkb1flox/ (KLC) PanINs and con-
rmed that Ki67 expression was elevated significantly in
dx1-Cre, KrasG12D/, Lkb1flox/ (KLC) PanINs, compared
ith Pdx1-Cre, KrasG12D/ (KC) PanINs (median % Ki67-
ositive cells: KC  10.4, KLC  79.9; P  .0006, data
ot shown). We performed immunohistochemistry for
urther markers of senescence/growth arrest, and ob-
erved increased expression of p16Ink4a and IgfBP7 and
ecreased levels of the replication licensing protein
CM2 in Pdx1-Cre, KrasG12D/ (KC) mice compared with
dx1-Cre, KrasG12D/, Lkb1flox/ (KLC) mice (Figure 5). We
id not, however, observe any significant differences in
evels of p19ARF (Figure 5, far-right panels). These data
uggest that Lkb1 acts as a tumor suppressor in the
ancreas by inducing p21 expression. Thus, a reduction
n Lkb1 levels leads to loss of p21 expression and escape
rom Ras-induced growth arrest.
p21 Heterozygosity Accelerates KrasG12D-
Induced Pancreatic Cancer
In order to examine this hypothesis further, we
ested whether p21 deficiency could similarly cooperate,
n place of Lkb1, with activated Kras to induce pancreatic
umorigenesis. We crossed p21/ (Cdkn1a/) mice into
ur model to generate Pdx1-Cre, KrasG12D/, p21/
KCp21) mice. These mice all developed PanIN lesions by
weeks of age, at an incidence similar to that observed in
dx1-Cre, KrasG12D/, Lkb1flox/ (KLC) mice, and at signif-
cantly increased incidence compared with Pdx1-Cre,
rasG12D/ (KC) mice (Figure 6A; P .02). These Pdx1-Cre,
rasG12D/, p21/ (KCp21) mice were also affected by a
warfism phenotype. Potentially, this was a result of
ancreatic islet insufficiency (Supplementary Figure 3),
hich required that mice be sacrificed early (disease-free
urvival shown in Figure 6B). Importantly though, PanIN
esions in these mice did progress to form PDAC (Figure
C) in 6 of 13 mice, with a median age at sacrifice of 75
ays, while the remaining mice exhibited widespread neo-
lastic changes at time of sacrifice. We did not observe
ny senescence-associated -galactosidase staining of
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ice, in contrast with PanIN lesions in Pdx1-Cre,
rasG12D/ (KC) mice (Figure 6E). Moreover, we observed
ecreased expression of p16Ink4a and IgfBP7 and increased
evels of MCM2 in Pdx1-Cre, KrasG12D/ p21/ (KCp21)
ice compared with Pdx1-Cre, KrasG12D/ (KC) mice (Fig-
re 6F). These results were analogous to those observed
n Pdx1-Cre, KrasG12D/, Lkb1flox/ (KLC) mice, but in con-
rast to the growth arrest/senescence and long latency of
umor development in Pdx1-Cre, KrasG12D/ (KC) animals.
ur findings suggest that loss of a single copy of p21 or
f Lkb1 is sufficient to overcome KrasG12D-induced
igure 4. Lkb1 deficiency accelerates KrasG12D-mediated pancreatic
taining for p53, p21, and Ki67, and senescence-associated -gal s
rasG12D/ (KC) mice. (B) Immunohistochemical staining for p53, p21
dx1-Cre KrasG12D/ Lkb1flox/ (KLC) mice (Supplementary Figure 2 for h
n PanINs in KC mice compared with KLC mice (n  6) as indicated (P
ice compared with KLC mice (n  6) as indicated (P  .004).rowth arrest/senescence in the pancreas. mWe also found that in these Pdx1-Cre, KrasG12D/ p21/
KCp21) animals, p53 was not activated in PanINs, and
o accumulation of p53 protein was observed in PDAC
Figure 6D), suggestive of the lack of mutation in p53,
ecause p53 mutation frequently results in accumulation
f the mutant protein. To further validate this Lkb1-p53-
21 axis in pancreatic tumorigenesis, we crossed Pdx1-
re, KrasG12D/, Lkb1fl/ (KLC) mice with Pdx1-Cre,
rasG12D/, p53R172H/ (KPC) mice, and with Pdx1-Cre,
rasG12D, p21/ (KCp21) mice to generate triple heterozy-
ous Pdx1-Cre, KrasG12D/, Lkb1fl/, p53R172H/ (KLPC
ice), and Pdx1-Cre, KrasG12D/, Lkb1fl/, p21/ (KLCp21)
rigenesis through down-regulation of p21. (A) Immunohistochemical
g in pancreatic intraepithelial neoplasia (PanIN) lesions in Pdx1-Cre
Ki67, and senescence-associated -gal staining in PanIN lesions in
agnification images). (C) Boxplot showing quantification of p21 staining
2). (D) Boxplot showing quantification of p53 staining in PanINs in KCtumo
tainin
, and
igh-m
 .00ice. We observed no acceleration of PDAC formation in
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August 2010 LKB1 DEFICIENCY AND PANCREATIC CANCER 593ither triple mutant mice compared with the correspond-
ng double mutants, indicative of genetic epistasis be-
ween Lkb1 deficiency and p53/p21 deficiency (P  .91
nd .61, respectively, Supplementary Figure 4). These
ata strongly support our hypothesis that Lkb1 defi-
iency can substitute for p53 mutation in pancreatic
ancer through loss of p21 regulation.
Decreased Lkb1 Expression in Human PDAC
Correlates With Low p21 Expression and
Reduced Survival
We next sought to investigate whether this Lkb1/
21 pathway was relevant to human PDAC development.
kb1 and p21 immunohistochemistry was performed in
tissue microarray containing 114 cases of primary hu-
an PDAC. As expected, we observed Lkb1 staining pri-
arily in the cytoplasm of epithelial cells (Figure 7A),
hile p21 staining was evident in the nuclear compart-
ent (Supplementary Figure 5). Lkb1 staining was
resent in 98% of stained normal ductal tissue. In PDAC,
9% of cases expressed Lkb1 at a low level (histoscore
100). Expression levels of Lkb1 did not differ in terms
f lymph node status or tumor size; however, high tumor
rade and stage were significantly associated with lower
edian Lkb1 expression level (Figure 7B; P .01 and P
02, respectively). In univariate analysis, low Lkb1 expres-
ion (n  20) was associated with significantly decreased
urvival compared with high expression (n  86) after
esection (Figure 7D, left panel, 11.6 months (95% confi-
igure 5. (A) Immunohistochemical staining for MCM2, p16, IgfBP7, a
rasG12D/ (KC) mice. (B) Immunohistochemical staining for MCM2, p16
ice.ence interval [CI]: 5.7–17.5] vs 19.6 months [95% CI: h3.5–20.6]; P .006). Most importantly, in a multivariate
ox proportional-hazards regression analysis, low Lkb1
xpression remained an independent predictor of poor
urvival, with a hazard ratio of 1.87 (95% CI: 1.09–3.22;
 .022).
Given our preclinical data suggesting that low Lkb1
evels caused low levels of p21, we next investigated the
xpression of p21 on the same human PDAC tissue
icroarray. Expression levels of p21 were not signifi-
antly altered in relation to any clinicopathological pa-
ameter; however, low expression of p21 (n  78) was
ssociated with decreased cumulative survival after sur-
ical resection, compared with high expression (n  28)
Figure 7D, right panel, 16.2 months [95% CI: 12.3–20.0] vs
5.7 months [95% CI: 11.7–40.2]; P .035). Strikingly, in
hese human PDAC cases, Lkb1 expression was demon-
trated to correlate directly with p21 expression (Figure
C, Spearman’s  correlation coefficient 0.34; P  .001).
ignificantly, high expression of both Lkb1 and p21 iden-
ified a group of patients with a more favorable out-
ome and a median survival of 25.7 months (Figure 7E,
5% CI: 12.9–40.3). Other predictors of poor survival
ere higher tumor stage, high histologic grade, larger
umor size, and positive resection margin; however, p21
tatus did not independently influence outcomes (Sup-
lementary Table 1).
Because the TP53 tumor suppressor gene is frequently
utated in human pancreatic cancer (40%–70%)30 and
KB1 is down-regulated in around 20% of PDAC, we
9ARF in pancreatic intraepithelial neoplasia (PanIN) lesions in Pdx1-Cre
P7, and p19ARF in PanIN lesions in Pdx1-Cre KrasG12D/ Lkb1flox/ (KLC)nd p1
, IgfBypothesized that loss of Lkb1-mediated p53/p21 induc-
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594 MORTON ET AL GASTROENTEROLOGY Vol. 139, No. 2ion might be able to circumvent the need for p53 mu-
ation in human PDAC and thus should not be down-
egulated in those tumors with p53 mutation. We
igure 6. (A) Boxplot showing number of pancreatic intraepithelial neoplas
nd KCp21 mice (n 6) as indicated. (B) Kaplan–Meier survival curve sho
3), and Pdx1-Cre KrasG12D/ p21/ mice (KCp21, solid blue line, n 13
KCp21 mouse. (D) Immunohistochemical staining for p53 in PDAC and
esions from KC and KCp21 mice. (F) Immunohistochemical staining for the sherefore investigated levels of p53 accumulation, indic- ltive of p53 mutation, by immunohistochemical staining
f the human PDAC tissue microarray. Strikingly, in
hose tumors that had low levels of LKB1, and, hence,
anINs) per histopathological section of pancreas from wild-type, KC, KLC,
disease-free survival of Pdx1-Cre p21/ mice (p21, broken red line, n
H&E-stained section of a pancreatic ductal adenocarcinoma (PDAC) from
arising in KCp21 mice. (E) Senescence-associated -gal staining in PanIN
ence markers p16, IgfBP7, and MCM2 in PanIN lesions from KCp21 mice.ias (P
wing
). (C)
PanINow levels of p21, we did not observe accumulation of
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ontrast, in the subset of tumors that had low p21 with
igh LKB1 expression, we found significantly higher lev-
ls of p53, indicative of accumulation of mutant p53
median histoscore  71.3, n  58, P  .05) (Figure 7F).
n human pancreatic cancer, we have shown that Lkb1
eficiency correlates with loss of p21 expression and with
oorer prognosis, and that Lkb1 deficiency may act as an
lternative to p53 mutation in human pancreatic tumor-
genesis. These results support the hypothesis that Lkb1
cts as a tumor suppressor in the pancreas, and that it
unctions, at least in part, by inducing p21 expression.
oss of Lkb1 can thus facilitate escape from Ras-induced
21-mediated growth arrest, and promote Ras-induced
igure 7. Decreased Lkb1 expression in human pancreatic ductal a
urvival. (A) Lkb1 immunostaining of duct and PDAC on human tissue
kb1 expression (median histoscore, 128) vs high-grade tumors (n 33
evel of Lkb1 expression (median histoscore, 150) vs stage T3 tumors (
ith p21 protein expression in 106 cases of PDAC (Spearman’s rho corr
ith low Lkb1 expression (n 20) have poorer outcomes compared to
xpression (n  78) have poorer outcomes compared to those with hi
kb1hi/p21hi patients have a more favorable outcome compared to Lkb1
umors (blue bar, n  20) compared with Lkb1hi/p21lo tumors (red bar,umorigenesis in the pancreas. iDiscussion
These data show that Lkb1 haploinsufficiency
ynergizes with activated Kras in pancreatic tumorigene-
is. Mechanistically, we believe this is because of reduced
rowth arrest/senescence through low levels of p21 in
DAC from these mice. Importantly, our study of human
DAC strongly supports this finding, as low levels of p21
nd LKB1 are correlated in human PDACs. Our data are
onsistent with the previous findings that Lkb1 loss pre-
ents culture-induced cellular senescence,13 allows BRAF
utant melanoma cells to proliferate,31 and cooperates
ith activating Kras mutations in a mouse model of lung
ancer.32 Indeed, our studies in both the pancreas and
carcinoma (PDAC) correlates with low p21 expression and reduced
array (TMA). (B) Low-grade tumors (n  81) exhibited a higher level of
dian histoscore, 100) (P .01). Stage T2 tumors (n 13) had a higher
11) (median histoscore, 105) (P  .02). (C) Correlation of Lkb1 protein
n coefficient 0.34; P .001). (D) Kaplan–Meier analyses showing cases
with high expression (n 86; P .006), and that cases with p21 low
pression (n  28; P  .035). (E) Kaplan–Meier analysis illustrates that
lo and Lkb1lo /p21lo cases. (F) Boxplot of p53 histoscore in Lkb1lo/p21lo
58) (P  .05).deno
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596 MORTON ET AL GASTROENTEROLOGY Vol. 139, No. 2eterozygosity for Lkb1 sufficient to drive signaling
ownstream of Kras.33 Overall, these data indicate that
evels of Lkb1 are critical in determining the cellular
esponse to Kras activation.
One important question that has been raised through
ur work and that of others13 is whether biallelic muta-
ions in LKB1 are required for tumorigenesis or whether
hey may in fact be limiting for tumor progression.
eutz–Jeghers syndrome patients develop benign hamar-
omas of the gastrointestinal tract and develop intraduc-
al papillary mucinous neoplasm and cystadenomas.
ere we have confirmed the previous study of Hezel and
olleagues,27 who showed that complete loss of Lkb1 in
he pancreas leads to formation of benign cystadenomas.
aken together, these data argue that complete loss of
kb1 leads to formation of benign tumors, that a coop-
rating oncogenic event is required to drive carcinoma
ormation, and that the timing of the cooperating onco-
enic event may be critical—if it occurs too late the tumor
ay not progress from a benign state. From the data
resented here, we suggest that in sporadic cancer, a
ingle LKB1 mutation or down-regulation of protein ex-
ression would be sufficient to synergize with KRAS mu-
ation to drive tumor progression. Analysis of human
ancreatic cancers is consistent with this hypothesis; 20
f 106 tumors show a down-regulation of LKB1 com-
ared to normal ductal epithelium and, remarkably, low
evels of LKB1 can act as an independent prognostic
ndicator of poor outcomes of resected pancreatic cancer.
n agreement with our findings in the pancreas, when the
KB1 gene sequence was determined in primary lung
denocarcinomas, only 8 of 27 tumors (of 80 cancers
otal) that had a mutation or deletion of LKB1 exhibited
iallelic loss,32 suggesting that a monoallelic mutation in
KB1 is sufficient to drive cancer progression. The lack of
KB1 mutations so far observed in human RAS-driven
ancreatic tumors may instead be explained by down-
egulation at the protein level, or inactivation of the gene
y epigenetic means, because hypermethylation of Lkb1
n hamartomatous polyps and in tumors commonly as-
ociated with Peutz–Jeghers syndrome has been demon-
trated in the absence of mutation of the gene.34
We propose that the mechanism for the synergy be-
ween Lkb1 heterozygosity and Kras activation is an es-
ape from KrasG12D-induced growth arrest by loss of p53
ediated p21 up-regulation. The reasons for this are
ultiple, including increased numbers of PanINs in
dx1-Cre, KrasG12D/, Lkb1flox/ (KLC) mice, increased pro-
iferation of PanINs, concomitant reduced expression
evels of p53 and p21, reduced expression of senescence-
ssociated -galactosidase, rapid tumorigenesis in Pdx1-
re, KrasG12D/, p21/mice, and the human data showing
he correlation between LKB1 and p21 levels. Remark-
bly, no human tumors that had low Lkb1 expression
ad high p21 expression. There was a subset of human
umors that had low p21 with high LKB1 expression,resumably because of the fact that multiple different
vents can cause p21 down-regulation, for example, p53
utation or TBX2 overexpression.35 Indeed, this group
f tumors exhibited high levels of p53, indicative of
utant p53 accumulation, suggesting that Lkb1 defi-
iency can substitute for p53 mutation in human pan-
reatic tumorigenesis.
Given the plethora of pathways that LKB1 impinges
n, it is likely that other pathways may also contribute to
he phenotype we see here. However, we failed to see clear
p-regulation of phosphomammalian target of rapa-
ycin within the Pdx1-Cre, KrasG12D/, Lkb1flox/ (KLC)
anINs and tumors when compared with the Pdx1-Cre,
rasG12D/ (KC) PanINs and tumors, although we clearly
ee reduced levels of the target phospho-AMPK (data not
hown). It is possible that within the pancreas, reduced
MPK activation is not sufficient to exert a clear pheno-
ype and indeed heterozygous AMPK knockout mice
ave no reported phenotype.36 Other potential pheno-
ypes of LKB1 deficiency, such as a loss of polarity and
ifferentiation to mucus secretory lineages, could accel-
rate tumorigenesis in this system.27,37,38 However, one of
he characteristics of Kras-driven PanINs is an increase in
ucin secretion and loss of polarity and, because het-
rozygosity for Lkb1 has never been sufficient to drive
ither of these 2 events, we believe that these are not
ajor contributors to our phenotype, although they may
ct in synergy with Kras activation.
In conclusion, we have shown that Lkb1 heterozygosity
an accelerate KrasG12D-induced PDAC formation. We
ave observed a marked reduction of p53 and p21 ex-
ression in PanIN lesions in these mice compared with
ice bearing intact Lkb1. This correlation is borne out in
uman PDAC. We therefore propose that Lkb1 acts as a
umor suppressor in the pancreas through its ability to
imit the p53/p21 pathway, thus allowing precursor le-
ions to more easily overcome the Ras-induced growth-
rrest barrier to tumor formation.
Supplementary Material
Note: To access the supplementary material
ccompanying this article, visit the online version of
astroenterology at www.gastrojournal.org, and at doi:
0.1053/j.gastro.2010.04.055.
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Genetically Modified Mice and Animal Care
Animals were kept in conventional animal facili-
ies and monitored daily. Experiments were carried out in
ompliance with UK Home Office guidelines. Mice were
enotyped by polymerase chain reaction analysis. Tumor
nd metastatic burden was assessed by gross pathology
nd histology. Animals were sacrificed by cervical dislo-
ation as per institutional guidelines. Organs/tumors
ere removed and either fixed in 10% buffered formalin
vernight at room temperature or snap frozen in liquid
itrogen. Fixed tissues were paraffin-embedded, and
-m sections were placed on sialynated/poly-L-lysine
lides for immunohistochemical analysis.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections were
eparaffinized and rehydrated by passage through Xylene
nd a graded alcohol series. Endogenous peroxidase ac-
ivity was inactivated by treatment with 3% hydrogen
eroxide, after which antigen retrieval was performed
sing microwave-heated antigen unmasking solution
Vector Labs, Burlingame, CA) or by incubation in citrate
uffer in a pressure cooker. Sections were blocked in 5%
erum for an hour, and then incubated with primary
ntibody for an hour at room temperature or overnight
t 4°C. Primary antibodies used were anti-Lkb1 (Abcam,
ambridge, UK) 1:200, anti-pAMPK (Cell Signaling Tech-
ology) 1:50, anti mouse p53 (Vector) 1:100, anti-p21
Santa Cruz Biotechnologies, Santa Cruz, CA) 1:500, anti-
i67 (Vector) 1:200, and anti-human p53 (Dako, Carpin-
eria, CA). Sections were incubated in secondary antibody
or an hour (Dako Envision Kit, or Vectastain ABC
ystem) and the staining was visualized with 3,3=-diami-
obenzidine tetrahydrochloride. Alcian blue staining was
arried out by incubation in Alcian blue solution (pH 2.5)
or 30 minutes, followed by counterstaining in nuclear
ast red solution for 5 minutes.
Reverse-Transcriptase Polymerase Chain
Reaction
Polymerase chain reactions were performed on aTC-200 DNA Engine (Bio–Rad Laboratories, Hercules, uA), using the GoTaq polymerase kit (Promega, Madi-
on, WI) according to manufacturer’s instructions. Poly-
erase chain reaction products were run on a 2% agarose
el, stained with ethidium bromide, and visualized using
he GelDoc-It 300 imaging system (UVP, Cambridge, UK).
rimers sequences used were: Lkb1 F: GGTCACACTTTA-
AACATCAC, and R: CTCATACTCCAACATCCCTC.
Tissue Microarray Analysis
All patients gave written, informed consent for the
ollection of tissue samples, and the local Research Ethics
ommittee approved collection. All cases had undergone
standardized pancreaticoduodenectomy. A total of
500 cores from a total of 224 cases with pancreatico-
iliary cancer (including 114 pancreatic ductal adenocar-
inomas) with a full spectrum of clinical and pathologi-
al features were arrayed in slides. At least 6 tissue cores
0.6 mm diameter) from tumor and 2 from adjacent
ormal tissue were sampled. Complete follow-up data
ere available for all cases within the tissue microarray
nalysis. Lkb1, p21, and p53 expression levels were scored
ased on staining intensity and area of tumor cells using
weighted histoscore calculated from the sum of (1  %
eak staining)  (2  % moderate staining)  (3  %
trong staining), providing a semi-quantitative classifica-
ion of staining intensity. The cutoff for high and low
xpression of Lkb1 and p21 was a histoscore of 100 and
0, respectively. Statistical correlation between Lkb1 ex-
ression and p21 expression in human PDAC was deter-
ined by the Spearman Correlation Coefficient analysis.
aplan–Meier survival analysis was used to analyze the
verall survival from the time of surgery. Patients alive at
he time of follow-up point were censored. To compare
ength of survival between curves, a log-rank test was
erformed. A Cox proportional hazards model was used
or univariate analysis to adjust for competing risk fac-
ors, and the hazard ratio with 95% CIs was reported as
n estimate of the risk of disease-specific death. Variables
hat were found to be significant on univariate analysis at
 .10 were included in multivariate analysis in a back-
ard stepwise fashion. Statistical significance was set at a
value of .05. All statistical analyses were performed
sing SPSS version 15.0 (SPSS Inc, Chicago, IL).
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August 2010 LKB1 DEFICIENCY AND PANCREATIC CANCER 597.e2upplementary Figure 1. Western immunoblotting analysis of Lkb1
top panel) and phosphoadenosine monophosphateactivated pro-
ein kinase (AMPK) (bottom panel) protein levels in pancreatic tumor
ysates from KC, KLC, and LLC mice. Levels were normalized against
-tubulin levels.
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597.e3 MORTON ET AL GASTROENTEROLOGY Vol. 139, No. 2upplementary Figure 2. Lkb1 deficiency accelerates KrasG12D-mediated pancreatic tumorigenesis through down-regulation of p21. (A) Immu-
ohistochemical staining for p53, p21, and Ki67 in pancreatic intraepithelial neoplasia (PanIN) lesions in Pdx1-Cre KrasG12D/ (KC) mice. (B)mmunohistochemical staining for p53, p21, and Ki67 in PanIN lesions in Pdx1-Cre KrasG12D/ Lkb1flox/ (KLC) mice.
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August 2010 LKB1 DEFICIENCY AND PANCREATIC CANCER 597.e4upplementary Figure 3. p21 haploinsufficiency synergizes with KrasG12D to induce pancreatic cancer and a dwarfism phenotype. (A) In vivo
maging of green fluorescent protein (GFP) fluorescence within the pancreas of a Pdx1-Cre KrasG12D/ Cdkn1a/ (KCp21) mouse at 6 weeks old;
21 deficiency allows outgrowth of recombined, and therefore, KrasG12D-bearing cells. (B) Loss of senescence-associated -galactosidase staining
n pancreatic intraepithelial neoplasia (PanIN) lesions from KCp21 mice, compared with that seen in PanIN lesions arising in Pdx1-Cre KrasG12D/ (KC)
ice. (C) Photograph demonstrating dwarfism phenotype in 6-week-old KCp21 mouse compared with a Pdx1-Cre CdKn1a/littermate control. (D)
epresentative H&E-stained sections showing reduced islet size in the pancreata of KCp21 mice, compared with Pdx1-Cre Cdkn1a/ control mice.
E) Boxplot showing number of islets per histopathological section of pancreas from KCp21 and KC mice as indicated (P  .00008). (F) Boxplot
howing quantification of islet volume per histopathological section of pancreas from KCp21 and KC mice as indicated (P  .007).
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597.e5 MORTON ET AL GASTROENTEROLOGY Vol. 139, No. 2upplementary Figure 4. (A) Kaplan–Meier survival curve showing
umor-free survival of littermate Pdx1-Cre KrasG12D/ Lkb1fl/ mice
KLC, broken blue line) and Pdx1-Cre KrasG12D/ Lkb1fl/ Trp53R172H/
ice (KLPC, solid red line). (B) Kaplan–Meier survival curve showing
umor-free survival of littermate Pdx1-Cre KrasG12D/ Lkb1fl/ mice
KLC, broken blue line) and Pdx1-Cre KrasG12D/ Lkb1fl/ p21/ mice
KLCp21, solid red line).
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August 2010 LKB1 DEFICIENCY AND PANCREATIC CANCER 597.e6upplementary Figure 5. p21 expression in human pancreatic ductal adenocarcinoma. (A) p21 immunostaining of normal pancreatic ductal
issue on human tissue microarray (TMA). (B–E) Representative immunostaining of p21 in pancreatic ductal adenocarcinoma on human TMA: (B)
bsent, (C) weak, (D) moderate, and (E) strong staining.upplementary Table 1. Multivariate Cox Regression
Analysis of Association of Lkb1,
p21 and Clinicopathological
Parameters with Overall Survival
Hazard
ratio 95% CI P value
umor stage (T3 vs T2) 2.20 1.204.41 .014
umor size (30 mm vs 30
mm)
1.65 1.092.51 .02
esection margin status (positive
vs negative)
1.97 1.163.4 .012
umor grade (high vs low) 2.54 1.604.11 .001
ascular invasion (yes vs no) 1.18 0.811.72 .38
21 (Histoscore 40 vs 40) 1.09 0.651.84 .71
kb1 (Histoscore 100 vs 100) 1.87 1.093.22 .023I, confidence interval.
